glp 1 with least side effects Your guide to GLP-1 GLP-1 Agonists For Obesity In

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors

In this narrative review we introduce the preclinical data related to this receptor pathway and pancreatic ductal adenocarcinoma

Analysis of nearly 8,000 adults found 45% keep the weight off after one year

Results Despite heterogeneity in study designs and populations, a largely consistent association was found between GLP-1RA use and a reduced incidence of glaucoma